External control arms and debunking real-world data myths
pharmaphorum
AUGUST 31, 2021
However, like many other emerging healthcare technologies, they have been slow to gain traction and there is still confusion and scepticism around ECAs, stemming from a lack of precedence, step-by-step guidance and data to quantify their impact on drug development costs and clinical outcomes.
Let's personalize your content